Advancing Medicine
with Extracellular Vesicle Innovation.

EVイノベーションで、医療を前へ。

We develop next-generation therapeutics using the unique biological functions of extracellular vesicles (EVs), aiming for long-lasting and clinically meaningful treatments in respiratory medicine.

About Us

“Being a pioneer
in innovative extracellular vesicle medicine”

Extracellular vesicles (EVs) serve as vital messengers in cell-to-cell communication, carrying a rich cargo of nucleic acids and proteins. Unlike conventional small molecules, antibodies, or synthetic DDS, EVs deliver a unique "multi-target" therapeutic effect through the synergy of these diverse molecules. At EVerMed, we believe in the transformative potential of EVs and are dedicated to pioneering their application as next-generation therapeutics.

研究・医療に関わるメンバーのイメージ

Our Mission

“Being a pioneer in innovative extracellular vesicle medicine”
We develop transformative EV pipelines while building the platform to industrialize EV therapeutics.

Members

Led by globally recognized EV scientists and experienced biotech leaders, EVerMed bridges scientific excellence with strategic execution.

Partnerships

We seek pharmaceutical, biotech, academic, and strategic partners who share our vision to advance EV therapeutics and build the future of EV medicine.

EVs are

Extracellular vesicles (EVs) are nano-sized vesicles secreted by cells that play a pivotal role in intercellular communication. We recognize EVs as a next-generation therapeutic modality, focusing specifically on the following key characteristics:

Natural nanoparticles (40–150 nm) that deliver cargo to cells

Multifunctional mechanisms of action

Carry diverse biomolecules (miRNA, mRNA, proteins)

Enable co-delivery of multiple cargos

Extracellular vesicles illustration
Pipeline image

Pipeline

Our pipeline focuses on addressing significant unmet medical needs in respiratory diseases by targeting the fundamental mechanisms underlying disease progression.

Through both extracellular vesicle (EV)-based therapeutics and small-molecule approaches, we aim to modulate pathological processes such as cellular senescence, aberrant tissue remodeling, and fibrosis, thereby enabling both disease suppression and tissue regeneration.

Our Partners

Get in Touch with Our Team

Examples of Inquiries

  • Collaboration or joint research opportunities
  • Technology evaluation or licensing inquiries
  • Partnership discussions with pharma companies
  • Investor or business development inquiries
  • Requests for scientific data or technical information